Neuphoria Therapeutics Inc.

NEUP Healthcare Biotechnology

Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.

3.30 0.01 −0.30%
Market cap
$17.9M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
n/a
Altman Z
−7.55
Beneish M
831.96
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
27.85 14.31 9.04 2.72
Net Debt/EBITDA
3.04 18.59 5.71 2.50
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
0.28 (0.62) (1.42) (1.69)
Book value per Share
5.60 5.44 6.55 5.57
Free Cash Flow
1.21 (3.34) (6.44) (3.79)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026